<DOC>
	<DOCNO>NCT02713256</DOCNO>
	<brief_summary>An open label study evaluate safety efficacy CFZ533 follow 12 week treatment patient Graves ' disease</brief_summary>
	<brief_title>A Study Evaluate Safety Effect CFZ533 Patients With Graves ' Disease</brief_title>
	<detailed_description />
	<mesh_term>Graves Disease</mesh_term>
	<criteria>Key 1 . Male female patient 18 65 year age include . Women childbearing potential must willing use highly effective method contraception study treatment epoch 12 week last study treatment . 2 . Grave 's hyperthyroidism diagnose prior screen . 3 . Patients must weigh least 40 kg participate study . Key 1 . History treatment Graves ' disease radioiodine ablation thyroidectomy and/or current treatment antithyroid drug ( methimazole propylthiouracil ) within one week start study treatment . 2 . History hyperthyroidism cause Graves ' disease ( e.g . toxic multinodular goiter , autonomous thyroid nodule , acute inflammatory thyroiditis ) and/or history presence thyroid storm ( fever , profuse sweating , vomit , diarrhea , delirium , severe weakness , seizure , markedly irregular heartbeat , yellow skin eye ( jaundice ) , severe low blood pressure , coma ) . 3 . Previous treatment B celldepleting biologic agent immunemodulatory biologic agent within 5 halflives ( experimental approve ) . 4 . History recurrent clinically significant infection recurrent bacterial infection encapsulate organism . 5 . History primary secondary immunodeficiency , include positive HIV ( ELISA Western blot ) test result . 6 . History evidence tuberculosis either follow test : Positive PPD skin test ( size induration measure 4872 hour , positive result define induration â‰¥ 5mm accord local practice/guidelines ) OR Positive QuantiFERON TBGold test 7 . Plans immunization live vaccine within 2month period enrollment study period . 8 . Treatment immunomodulatory drug , cyclosporine A , methotrexate , and/or cyclophosphamide within 3 month baseline . Glucocorticosteroid therapy prednisolone 10 mg daily permit patient stable dose 3 month enrollment study . 9 . Pregnant , breastfeed female , woman child bear potential unless use highly effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Graves ' disease</keyword>
	<keyword>Hyperthyroidism</keyword>
	<keyword>CFZ533</keyword>
	<keyword>TSH</keyword>
</DOC>